Association between plasma macrophage migration inhibitor factor and deep vein thrombosis in patients with spinal cord injuries.

Dong-Mei Wu,Zi-Hui Zheng,Shan Wang,Xin Wen,Xin-Rui Han,Yong-Jian Wang,Min Shen,Shao-Hua Fan,Zi-Feng Zhang,Qun Shan,Meng-Qiu Li,Bin Hu,Yuan-Lin Zheng,Gui-Quan Chen,Jun Lu
DOI: https://doi.org/10.18632/aging.101935
2019-01-01
Abstract:The patients with spinal cord injury (SCI) suffered significantly higher risk of deep vein thrombosis (DVT) than normal population. The aim was to assess the clinical significance of macrophage migration inhibitory factor (MIF) as the risk factor for DVT in acute SCI patients. 207 Chinese patients were enrolled in this study, including thirty-nine (39) patients (18.8 %; 95 % CI: 13.5 %-24.2 %) diagnosed as DVT at the follow-up of 1 month. Nine (9) of the 39 patients (23.1%) were suspected of thrombosis before the screening. The MIF levels in plasma of DVT patients were significantly higher than DVT-free patients. The risks of DVT would be increased by 11 % (OR (unadjusted): 1.11; 95% CI, 1.06-1.17, P<0.001) and 8 % (OR (adjusted): 1.08; 1.03-1.14, P=0.001), for each additional 1 ng/ml of MIF level. Furthermore, after MIF was combined with established risk factors, area under the receiver operating characteristic curve (standard error) was increased from 0.82(0.035) to 0.85(0.030). The results showed the potential association between the high MIF levels in plasma and elevated DVT risk in SCI patients, which may assist on early intervention.
What problem does this paper attempt to address?